Table 1.
Disease progression
| Baseline (n = 26) | Follow up (n = 26) | Difference (95% CI) | P‐value | |
|---|---|---|---|---|
| Clinical outcome measures | ||||
| EDSS | 3.5 (1.0‐6.0) | 3.5 (1.8‐6.0) | 0.21 (0.01‐0.42) | .042* |
| SSPROM | 91.0 (81.0‐100) | 87.0 (75.8‐100) | −2.23 (−4.43‐0.03) | .052 |
| 6MWT (n = 24) | 562.6 (±198.4) | 555.3 (±197.0) | −8.73 (−13.0‐27.5) | .464 |
| TUG (n = 23) | 4.7 (3.5‐9.1) | 5.2 (3.7‐9.0) | 0.23 (−0.41‐0.86) | .045* |
| Quantitative vibration score (internal malleolus) | 4.38 (1.06‐6.81) | 3.75 (0.19‐6.56) | −0.24 (−0.57‐0.09) | .199 |
| Quantitative vibration score (hallux) | 1.63 (0.00‐7.00) | 0.75 (0.00‐6.50) | −0.30 (−0.50‐0.10) | .007* |
| Spinal cord CSA (mm 2 ) | ||||
| C1 | 56.49 (11.03) | 56.16 (10.46) | 0.33 (−0.35‐1.00) | .330 |
| C2 | 53.36 (9.95) | 53.29 (10.79) | 0.07 (−0.75‐0.88) | .867 |
| C3 | 54.13 (9.81) | 54.04 (10.59) | 0.09 (−0.75‐0.93) | .823 |
| C4 | 58.78 (9.96) | 58.43 (10.39) | 0.34 (−0.69‐1.38) | .501 |
| C5 | 58.05 (11.08) | 58.18 (11.11) | −0.13 (−0.98‐0.73) | .763 |
| C6 | 51.54 (10.49) | 51.98 (10.25) | −0.44 (−1.57‐0.68) | .426 |
| C7 | 40.87 (10.10) | 41.66 (10.46) | −0.79 (−1.96‐0.37) | .174 |
| Th1 | 33.88 (8.86) | 33.89 (9.38) | −0.01 (−1.03‐1.01) | .981 |
| Th2 | 30.88 (8.58) | 30.85 (8.93) | 0.03 (−0.61‐0.67 | .917 |
Notes: Values are medians with IQRs or means with SDs. Differences between groups are analysed with Wilcoxon signed‐rank test or Paired t test. *P‐value statistically significant.
Abbreviations: EDSS, Expanded Disability Status Scale; SSPROM, Severity Scoring system for Progressive Myelopathy; 6MWT, 6 Minute Walk Test; TUG, Timed up‐and‐go; CSA, cross‐sectional area.